Press & media
Press kit.
Short descriptions, logo and contacts for articles, event programmes and partner pages.
In one sentence
Recanthia is a research-stage oncology project that develops transcriptomic analysis services to characterise treatment response and support R&D teams, starting with triple-negative breast cancer.
In one paragraph
Founded by Maxime Grember and Nathan Horochowska Laneret, researchers at the University of Lille, Recanthia combines cancer biology and computational analysis of regulatory networks. Its first research programme studies response to immunotherapy in triple-negative breast cancer. The company plans to launch B2B research services in 2027 and aims, after clinical validation, to develop decision-support applications.
Logo and visuals
Please note
- Recanthia is at research stage: please do not describe it as offering a validated test or clinical service.
- Clinical use, regulatory approval and reimbursement are goals, not achievements.
- Please contact us before quoting figures or naming partners.
Founders
